{"title":"Effectiveness of novel iron regulators in the treatment of diabetic nephropathy","authors":"Dekai Banerjee, Ginpreet Kaur, Bappaditya Chatterjee, Hemant Joshi, Seema Ramniwas, Hardeep Singh Tuli","doi":"10.15584/ejcem.2023.3.28","DOIUrl":null,"url":null,"abstract":"Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.","PeriodicalId":11828,"journal":{"name":"European Journal of Clinical and Experimental Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical and Experimental Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15584/ejcem.2023.3.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
介绍和目的。即将到来的用于治疗糖尿病肾病的铁调节剂的新进展涉及联合螯合治疗的共同表现,用于消除与炎症和铁失衡相关的终末期肾脏疾病,这是由肾铁吸收改变的。然而,铁在过滤血液的聚集性肾脏中的积累可能会导致影响糖尿病血糖调节的问题。材料和方法。采用精心设计的方法,发现铁螯合剂及其治疗糖尿病肾病的潜力的相关研究出版物。在Google Scholar、Web of Science、PubMed和EMBASE中搜索“铁螯合剂”、“糖尿病肾病”、“终末期肾病”和“螯合疗法”。文学分析。虽然具体的病因和发展尚未完全探索,但铁病理生理学的新证据有助于理解急性肾损伤和慢性肾脏疾病的发病机制,这至关重要地提供了新的铁螯合治疗技术。铁下垂和hepcidin标记蛋白增加氧化/硝化应激和肾损伤。铁螯合剂药物包括去铁胺、去铁铁素和去铁酮作为预防策略进行了测试。结论。本文涵盖了铁螯合剂的临床前和临床方面,以避免糖尿病肾病,包括在选择剂量方案时必须审查的新型铁疗法。